Long-term outcomes in half-dose verteporfin photodynamic therapy for chronic central serous retinopathy

Nadeem Ali Dhirani,1 Yelin Yang,2 Sohel Somani2–4 1Wayne State University School of Medicine, Detroit, MI, USA; 2Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, ON, 3William Osler Health System, Brampton, ON, 4Uptown Eye Specialists, Brampton, ON, Canada...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Dhirani NA, Yang Y, Somani S
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	central serous chorioretinopathy photodynamic therapy verteporfin half-dose verteporfin Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/fe50737c5636461a91493d5b859f8bd9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:fe50737c5636461a91493d5b859f8bd9
record_format	dspace
spelling	oai:doaj.org-article:fe50737c5636461a91493d5b859f8bd92021-12-02T08:39:12ZLong-term outcomes in half-dose verteporfin photodynamic therapy for chronic central serous retinopathy1177-5483https://doaj.org/article/fe50737c5636461a91493d5b859f8bd92017-12-01T00:00:00Zhttps://www.dovepress.com/long-term-outcomes-in-half-dose-verteporfin-photodynamic-therapy-for-c-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Nadeem Ali Dhirani,1 Yelin Yang,2 Sohel Somani2–4 1Wayne State University School of Medicine, Detroit, MI, USA; 2Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, ON, 3William Osler Health System, Brampton, ON, 4Uptown Eye Specialists, Brampton, ON, Canada Objective: To evaluate the short- and long-term outcomes of half-dose verteporfin with photodynamic therapy (PDT) in the treatment of chronic central serous retinopathy (CSR). Design: Retrospective case series.Participants: 45 eyes in 39 patients with chronic CSR were included. Diagnosis of chronic CSR was confirmed by fluorescein angiography and persistence of subretinal fluid by optical coherence tomography for a minimum of 3 months duration.Methods: Each patient underwent treatment with half-dose verteporfin with full-fluence PDT; initial follow-up was defined as a 6–8 week visit following the treatment, and final follow-up ranged from 5 to 70 months.Results: The average follow-up period for treatment was 19.3 months. Best-corrected visual acuity increased from logMAR means of 0.52 to 0.42 (p<0.05). Central retinal thickness and choroidal thickness also significantly decreased at last follow-up (p<0.05). Eight of 45 eyes (18%) demonstrated a recurrence of CSR following treatment within the follow-up period. At the final follow-up, 41 out of the 45 eyes (91%) had complete resolution of subretinal fluid accumulation.Conclusion: Half-dose PDT is an effective treatment option for chronic CSR in a Canadian population, and it is both safe and durable. The positive treatment effect is realized rapidly, with the initial 6-week result highly correlated with the final follow-up result. Keywords: central serous chorioretinopathy, photodynamic therapy, verteporfin, half-dose verteporfin Dhirani NAYang YSomani SDove Medical Pressarticlecentral serous chorioretinopathyphotodynamic therapyverteporfinhalf-dose verteporfinOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 11, Pp 2145-2149 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	central serous chorioretinopathy photodynamic therapy verteporfin half-dose verteporfin Ophthalmology RE1-994
spellingShingle	central serous chorioretinopathy photodynamic therapy verteporfin half-dose verteporfin Ophthalmology RE1-994 Dhirani NA Yang Y Somani S Long-term outcomes in half-dose verteporfin photodynamic therapy for chronic central serous retinopathy
description	Nadeem Ali Dhirani,1 Yelin Yang,2 Sohel Somani2–4 1Wayne State University School of Medicine, Detroit, MI, USA; 2Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, ON, 3William Osler Health System, Brampton, ON, 4Uptown Eye Specialists, Brampton, ON, Canada Objective: To evaluate the short- and long-term outcomes of half-dose verteporfin with photodynamic therapy (PDT) in the treatment of chronic central serous retinopathy (CSR). Design: Retrospective case series.Participants: 45 eyes in 39 patients with chronic CSR were included. Diagnosis of chronic CSR was confirmed by fluorescein angiography and persistence of subretinal fluid by optical coherence tomography for a minimum of 3 months duration.Methods: Each patient underwent treatment with half-dose verteporfin with full-fluence PDT; initial follow-up was defined as a 6–8 week visit following the treatment, and final follow-up ranged from 5 to 70 months.Results: The average follow-up period for treatment was 19.3 months. Best-corrected visual acuity increased from logMAR means of 0.52 to 0.42 (p<0.05). Central retinal thickness and choroidal thickness also significantly decreased at last follow-up (p<0.05). Eight of 45 eyes (18%) demonstrated a recurrence of CSR following treatment within the follow-up period. At the final follow-up, 41 out of the 45 eyes (91%) had complete resolution of subretinal fluid accumulation.Conclusion: Half-dose PDT is an effective treatment option for chronic CSR in a Canadian population, and it is both safe and durable. The positive treatment effect is realized rapidly, with the initial 6-week result highly correlated with the final follow-up result. Keywords: central serous chorioretinopathy, photodynamic therapy, verteporfin, half-dose verteporfin
format	article
author	Dhirani NA Yang Y Somani S
author_facet	Dhirani NA Yang Y Somani S
author_sort	Dhirani NA
title	Long-term outcomes in half-dose verteporfin photodynamic therapy for chronic central serous retinopathy
title_short	Long-term outcomes in half-dose verteporfin photodynamic therapy for chronic central serous retinopathy
title_full	Long-term outcomes in half-dose verteporfin photodynamic therapy for chronic central serous retinopathy
title_fullStr	Long-term outcomes in half-dose verteporfin photodynamic therapy for chronic central serous retinopathy
title_full_unstemmed	Long-term outcomes in half-dose verteporfin photodynamic therapy for chronic central serous retinopathy
title_sort	long-term outcomes in half-dose verteporfin photodynamic therapy for chronic central serous retinopathy
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/fe50737c5636461a91493d5b859f8bd9
work_keys_str_mv	AT dhiranina longtermoutcomesinhalfdoseverteporfinphotodynamictherapyforchroniccentralserousretinopathy AT yangy longtermoutcomesinhalfdoseverteporfinphotodynamictherapyforchroniccentralserousretinopathy AT somanis longtermoutcomesinhalfdoseverteporfinphotodynamictherapyforchroniccentralserousretinopathy
_version_	1718398443658936320

Long-term outcomes in half-dose verteporfin photodynamic therapy for chronic central serous retinopathy

Ejemplares similares